Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

215TiP - A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemo-radiotherapy (CRT): DURVALUNG trial

Date

22 Mar 2024

Session

Poster Display session

Topics

Tumour Site

Small Cell Lung Cancer

Presenters

Elisa Gobbini

Citation

Annals of Oncology (2024) 9 (suppl_3): 1-11. 10.1016/esmoop/esmoop102577

Authors

E. Gobbini1, T. Filleron2, S. Thureau3, L. Falchero4, J. Le Treut5, R. Bonetto6, M. Bernardi7, S. Benyoub8, L. Stoffaes9, C. SIMON10, A. Lamrani-Ghaouti11, J. Doyen12

Author affiliations

  • 1 Institut Curie, Paris/FR
  • 2 Institut Claudius Regaud - IUCT Oncopole, 31059 - Toulouse, Cedex/FR
  • 3 Centre Henri Becquerel, Rouen/FR
  • 4 L'Hopital Nord Ouest - Villefranche-Sur-Saone, Villefranche-Sur-Saone/FR
  • 5 Hôpital Européen Marseille, Marseille/FR
  • 6 Hopital Privé Clairval - Ramsay Santé, 13385 - Marseille/FR
  • 7 CH du Pays d'Aix, Aix-en-Provence/FR
  • 8 Centre de radiothérapie du Pays d'Aix, Aix-en-Provence/FR
  • 9 IPC - Institut Paoli-Calmettes, Marseille, Cedex/FR
  • 10 Unicancer, Paris, Cedex/FR
  • 11 Unicancer, 75654 - Paris, Cedex/FR
  • 12 Centre Anticancer Antoine Lacassagne, Nice/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 215TiP

Background

Small cell Lung Cancer (SCLC) is a rare tumour subtype, and approximately one third of the SCLC patients (pts) present limited disease (LD-SCLC) with a 5-year survival rate between 20% and 25%. The standard of care (SOC) is platinum-based chemotherapy combined with etoposide and thoracic radiotherapy (CRT). While immunotherapy is currently limited to advanced SCLC setting, NSCLC setting suggest that the combination of immunotherapy and radiotherapy may produce a synergistic effect. The relevance of a multimodal strategy including immunotherapy after CRT is therefore currently under investigation, but frail LD-SCLC pts are often excluded from clinical trials. Thus, DURVALUNG study aims to evaluate the efficacy of durvalumab maintenance specifically in frail LD-SCLC pts who have not progressed following concomitant or sequential CRT.

Trial design

DURVALUNG is an academically-lead, open-label, multicentre, randomized phase II trial in previously untreated frail LD-SCLC pts. Pts will be screened during the CRT and only those achieving a disease control (SD or PR/CR) after the CRT and presenting frail condition (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant CRT due to comorbidities) will be randomized 1:1 to receive durvalumab every 4 weeks for 24 months or surveillance as per SOC. Prophylactic Cranial Irradiation will be allowed according to local SOC within 45 days after the end of CRT. 110 pts will be randomized in the study. A safety interim analysis will be performed after the first 15 pts included into the experimental arm for the Data Safety Monitoring Board. The main objective is to evaluate the progression-free survival (PFS), per investigator, of LD-SCLC pts on durvalumab arm compared to surveillance. The primary endpoint analysis will be a Cox regression analysis with 90% confidence interval (1-sided). Secondary objectives are BIRC PFS, overall survival, quality of life, and toxicity. Ancillary studies will be conducted to determine biomarkers of clinical benefit from the durvalumab maintenance, the impact of sarcopenia on outcomes, and the correlation between radiotherapy plan and survival outcomes and toxicities.

Clinical trial identification

EudraCT: 2021-005920-39 NCT05617963.

Legal entity responsible for the study

Unicancer.

Funding

AstraZeneca.

Disclosure

E. Gobbini: Non-Financial Interests, Personal, Other, Spouse of an AstraZeneca employee: AstraZeneca; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, AstraZeneca; Financial Interests, Personal and Institutional, Other, Personal fees: Roche, Pfizer, Merck Sharpe and Dohme, Bristol Myers Squibb, Takeda, Janssen, Sanofi. T. Filleron: Financial Interests, Personal, Other, working group: Janssen-Cilag; Financial Interests, Institutional, Invited Speaker: Lilly; Financial Interests, Institutional, Other, working group: Roche; Other, Personal, Other, Consulting (compensated to my institution): Cellectis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.